Medpace (MEDP) Stock Price, News & Analysis

Company Overview

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Key Stats

• Today's Range: $365.88 to $374.16
• 50-Day Range: $327.80 to $457.29
• 52-Week Range: $227.21 to $459.77
• Volume: 312,896 shs
• Average Volume: 249,870 shs
• Market Capitalization: $11.44 billion
• P/E Ratio: 37.63
• Dividend Yield: N/A
• Price Target: $423.00
• Consensus Rating: Moderate Buy

Medpace Stock Analysis - MarketRank™

Medpace scored higher than 99% of companies evaluated by MarketBeat, and ranked 15th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Medpace has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Medpace has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 11.15%

Earnings Growth

Earnings for Medpace are expected to grow by 11.15% in the coming year, from $11.66 to $12.96 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Medpace is 37.63, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.13.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medpace is 37.63, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 118.42.

Price to Earnings Growth Ratio

Medpace has a PEG Ratio of 1.74. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Medpace has a P/B Ratio of 20.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.39% of the float of Medpace has been sold short.

Short Interest Ratio / Days to Cover

Medpace has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Medpace has recently decreased by 9.59%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medpace does not currently pay a dividend.

Dividend Growth

Medpace does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.62

Percentage of Shares Shorted

3.39% of the float of Medpace has been sold short.

Short Interest Ratio / Days to Cover

Medpace has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Medpace has recently decreased by 9.59%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 1.06

News Sentiment

Medpace has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Medpace this week, compared to 8 articles on an average week.

Search Interest

Only 6 people have searched for MEDP on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Medpace insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.30% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MEDP Stock Analysis - Frequently Asked Questions

How have MEDP shares performed this year?

Medpace's stock was trading at $306.53 at the beginning of 2024. Since then, MEDP stock has increased by 20.4% and is now trading at $369.18.
View the best growth stocks for 2024 here.

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) posted its quarterly earnings data on Monday, July, 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.54 by $0.21. Medpace's revenue for the quarter was up 14.6% on a year-over-year basis.

When did Medpace IPO?

Medpace (MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Who are Medpace's major shareholders?

Top institutional shareholders of Medpace include Riverbridge Partners LLC (1.73%), TD Asset Management Inc (1.65%), Renaissance Technologies LLC (1.43%) and Epoch Investment Partners Inc. (1.31%). Insiders that own company stock include Medpace Investors, Llc, August J Troendle, Susan E Burwig, Stephen P Ewald, Kevin M Brady, Ashley M Keating, Robert O Kraft and Tom C King.
View institutional ownership trends.

How do I buy shares of Medpace?

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD) and Bilibili (BILI).

Company Calendar

• Last Earnings: 7/22/2024
• Today: 9/19/2024
• Next Earnings (Estimated): 10/28/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Commercial physical research
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:MEDP
• CUSIP: N/A
• CIK: 1668397
• Web: www.medpace.com
• Phone: (513) 579-9911
• Fax: 513-579-0444
• Employees: 5,900
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $423.00
• High Stock Price Target: $452.00
• Low Stock Price Target: $336.00
• Potential Upside/Downside: +14.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $9.81
• Trailing P/E Ratio: 37.63
• Forward P/E Ratio: 31.66
• P/E Growth: 1.74
• Net Income: $282.81 million
• Net Margins: 16.74%
• Pretax Margin: 19.57%
• Return on Equity: 55.14%
• Return on Assets: 19.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.88
• Quick Ratio: 0.88

Sales & Book Value

• Annual Sales: $2.03 billion
• Price / Sales: 5.63
• Cash Flow: $11.12 per share
• Price / Cash Flow: 33.21
• Book Value: $18.22 per share
• Price / Book: 20.26

Miscellaneous

• Outstanding Shares: 30,983,000
• Free Float: 24,693,000
• Market Cap: $11.44 billion
• Optionable: Optionable
• Beta: 1.36